Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effect of Recombinant Human Thrombopoietin(rhTPO) on Sepsis Patients With Acute Severe Thrombocytopeniaa Prospective, Multi-center, Open-label, Randomized, Controlled Trial

Next Previous
Search
Trial Profile

The Effect of Recombinant Human Thrombopoietin(rhTPO) on Sepsis Patients With Acute Severe Thrombocytopeniaa Prospective, Multi-center, Open-label, Randomized, Controlled Trial

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 23 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Thrombopoietin (Primary)
  • Indications Thrombocytopenia
  • Focus Therapeutic Use
  • Acronyms RESCUE

Most Recent Events

  • 16 Apr 2024 Planned End Date changed from 30 Apr 2023 to 30 Sep 2024.
  • 16 Apr 2024 Planned primary completion date changed from 31 Mar 2023 to 31 Aug 2024.
  • 25 Oct 2022 Planned End Date changed from 30 Dec 2022 to 30 Apr 2023.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top